Please login to the form below

Not currently logged in
Email:
Password:

vintafolide

This page shows the latest vintafolide news and features for those working in and with pharma, biotech and healthcare.

Amgen's trebananib misses survival target in ovarian cancer

Amgen's trebananib misses survival target in ovarian cancer

Other candidates coming through the pipeline include Boehringer Ingelheim's triple angiokinase inhibitor nintedanib, Merck &Co's anti-folate drug vintafolide, AstraZeneca's PARP inhibitor olaparib and Array BioPharma/Novartis's

Latest news

  • Merck's vintafolide fails ovarian cancer trial Merck's vintafolide fails ovarian cancer trial

    Merck's vintafolide fails ovarian cancer trial. Major blow for drug’ s original developers Endocyte. ... PROCEED compared the combination of vintafolide and pegylated liposomal doxorubicin to a combination of doxorubicin and placebo.

  • EMA backs Janssen rare disease drug for approval EMA backs Janssen rare disease drug for approval

    it. Staying in the orphan disease area the CHMP also gave the nod to Endocyte's Vynfinit (vintafolide), a treatment for platinum-resistant ovarian cancer, along with two companion diagnostic drugs

  • Boehringer/Lilly's empagliflozin among CHMP recommendations Boehringer/Lilly's empagliflozin among CHMP recommendations

    There were also recommendations for four orphan drugs: Janssen-Cilag's Sylvant (situximab) and, along with the companion diagnostic drugs Folcepri (etarfolatide) and Neocepri (folic acid), Endocyte's Vynfinit (vintafolide).

  • Late-stage ovarian cancer Late-stage ovarian cancer

    Endocyte's vintafolide is a folate-targeted conjugate composed of a folate molecule plus a vinca alkaloid, which acts as a microtubule destabilising agent. ... Vintafolide targets and enters cancer cells via the folate vitamin receptor, which is

  • Merck's vintafolide shows its worth in ovarian cancer Merck's vintafolide shows its worth in ovarian cancer

    Merck's vintafolide shows its worth in ovarian cancer. Phase II data shows improvement on current oncology treatments. ... Vintafolide is a small molecule drug conjugate (SMDC) that combines folate with the cytotoxic agent vinblastine.

More from news
Approximately 3 fully matching, plus 11 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics